Is Celexa affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Used for: Depression, sometimes used for anxiety disorders

Considering GeneSight for Celexa?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data.

See the comparison →

Celexa (citalopram) is the racemic version of escitalopram, meaning it contains both the active S-enantiomer and the less-active R-enantiomer. Its pharmacogenetic story is driven by CYP2C19, and citalopram is the drug where the FDA has been most explicit about incorporating pharmacogenetic considerations into the label. In 2011, the FDA added a warning that citalopram doses above 40 mg per day can cause potentially dangerous QT interval prolongation, and specifically identified CYP2C19 poor metabolizers (who accumulate the drug at standard doses) as a population in whom the 20 mg daily maximum should apply.

What's in Celexa

citalopram affected by CYP2C19

Affected by CYP2C19 · CPIC, FDA · Strong evidence

Citalopram is cleared primarily by CYP2C19 with contributions from CYP3A4 and CYP2D6. CPIC guidelines recommend a 50 percent starting dose reduction for CYP2C19 poor metabolizers and consideration of an alternative (non-CYP2C19) drug for ultrarapid metabolizers. QT interval prolongation at higher plasma concentrations is the specific safety concern driving dose caps. The R-enantiomer contributes minimally to the antidepressant effect but may contribute to some of the dose-limiting side effects, which is part of the rationale for escitalopram (the S-enantiomer alone).

Read the full citalopram genetics guide →

Citalopram phenotype recommendations

Published guidance from CPIC and FDA on how citalopram should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	You may break down the drug too quickly, making it less effective. Your doctor may need to increase the dose or switch medications.	CPIC Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose. FDA Initiate therapy with recommended starting dose.	Moderate
Rapid Metabolizer CYP2C19	You may process the drug faster, reducing its effects. Your doctor may increase the dose or switch medications if needed.	CPIC Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. FDA Initiate therapy with recommended starting dose.	Moderate
Normal Metabolizer CYP2C19	Standard dosing is expected to work for you.	CPIC + FDA Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2C19	Your body may break down the drug more slowly, increasing side effects. Your doctor may use a lower dose or adjust it more slowly.	CPIC Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers. FDA Initiate therapy with recommended starting dose.	Strong
Likely Intermediate Metabolizer CYP2C19	Your body may break down the drug more slowly, so you might need a lower or slower-adjusted dose.	CPIC Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.	Strong
Likely Poor Metabolizer CYP2C19	You process the drug very slowly, which may raise side effects. A lower dose or a different medication may be needed.	CPIC Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule, and 50% reduction of the standard maintenance dose as compared with normal metabolizers.	Moderate
Poor Metabolizer CYP2C19	You break down the drug very slowly, increasing risk of side effects. Your doctor may lower the dose or switch to another medication.	CPIC Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule, and 50% reduction of the standard maintenance dose as compared with normal metabolizers. FDA Do not exceed a maximum dose of 20 mg daily due to risk of QT prolongation from higher systemic concentrations.	Strong
Indeterminate CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Browse the full drug-class: SSRI antidepressants.

What this means for you

Celexa has been on the market long enough that most prescribers are aware of the CYP2C19 dose considerations, but not all will proactively test. If you're starting or struggling with Celexa, asking about CYP2C19 testing is reasonable. Poor metabolizers should not exceed 20 mg daily per the FDA label. Rapid and ultrarapid metabolizers often fail to respond to 20 or 40 mg doses, and a different drug (rather than a higher dose) is usually the right move.

FAQ

Is Celexa the same as Lexapro?

Related but not the same. Celexa is citalopram (racemic, both enantiomers). Lexapro is escitalopram (the S-enantiomer only). They share the same CYP2C19-dependent pharmacogenetics, but Lexapro is generally dosed lower because only the active enantiomer is present.

Why does the Celexa dose matter so much?

At doses above 40 mg daily (or above 20 mg in CYP2C19 poor metabolizers or older adults), citalopram can prolong the QT interval, increasing the risk of a serious cardiac arrhythmia called torsades de pointes. The FDA placed a hard upper limit for this reason. It's not about the antidepressant effect plateauing (though that's also true); it's about cardiac safety.

If my CYP2C19 shows I'm an ultrarapid metabolizer, is there any reason to try citalopram at all?

Usually not, because achieving therapeutic plasma levels at the FDA-maximum 40 mg dose is unlikely. CPIC recommends starting with a non-CYP2C19-metabolized antidepressant for ultrarapid metabolizers. Fluoxetine, paroxetine, and the SNRIs like duloxetine and venlafaxine are typical alternatives your prescriber may consider.

Related medications

Find out how your genetics affect Celexa

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.